Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page shows an updated revision label 'Revision: v3.5.3' replacing the previous 'Revision: v3.5.2', indicating a software release rather than a change to the study data.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision: v3.4.3 has been added, replacing the previous v3.4.2. This is a minor UI/version update and does not change study details or user interactions on the page.SummaryDifference0.0%

- Check90 days agoChange DetectedRevision: v3.4.2 is now shown; notices about government funding lapses and Revision: v3.4.1 respectively have been removed.SummaryDifference0.3%

- Check97 days agoChange DetectedAdded a notice about a lapse in government funding and updated the revision to v3.4.1. The previous revision v3.4.0 was removed.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.